



Peptide-Based Vaccines against Infectious Diseases and Cancer

Guest Editors:

Dr. Waleed Hussein

Institute for Molecular
Bioscience, The University of
Queensland, Brisbane, Australia

Dr. Rachel Stephenson

School of Chemistry and
Molecular Biosciences, The
University of Queensland,
Brisbane, Australia

Dr. Mariusz Skwarczynski

School of Chemistry and
Molecular Biosciences, The
University of Queensland, St
Lucia, QLD 4072, Australia

Message from the Guest Editors

Vaccination is one of the most successful tools for reducing the incidence of infectious diseases. Peptide-based subunit vaccines have emerged as promising prophylactic and therapeutic medication against several infectious diseases including group A streptococcus, malaria, TB, and cancer. Peptide-subunit-based vaccines contain only the minimal immunogenic region of an antigen necessary to elicit the desired immune response. Therefore, only safe and effective epitopes can be selected, removing the risk of allergic and autoimmune responses. However, peptides do not contain the danger signals that are needed to activate the immune system. Thus, an adjuvant/delivery system must be included to stimulate an immune response against the peptide antigen.

Deadline for manuscript
submissions:

closed (31 October 2023)





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com